Literature DB >> 8641905

Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas.

B K Mohanti1, G K Rath, N Anantha, V Kannan, B S Das, B A Chandramouli, A K Banerjee, S Das, A Jena, R Ravichandran, U P Sahi, R Kumar, N Kapoor, V K Kalia, B S Dwarakanath, V Jain.   

Abstract

PURPOSE: Evaluation of tolerance, toxicity, and feasibility of combining large fraction (5 Gy) radiotherapy with 2-deoxy-D-glucose (2DG), an inhibitor of glucose transport and glycolysis, which has been shown to differentially inhibit repair of radiation damage in cancer cells. METHODS AND MATERIALS: Twenty patients with supratentorial glioma (Grade 3/4), following surgery were treated with four weekly fractions of oral 2DG (200 mg/kg body weight) followed by whole brain irradiation (5 Gy). Two weeks later, supplement focal radiation to the tumor (14 Gy/7 fractions) was given. Routine clinical evaluation, x-ray computerized tomography (CT), and magnetic resonance (MR) imaging were carried out to study the acute and late radiation effects.
RESULTS: All the 20 patients completed the treatment without any interruption. The vital parameters were within normal limits during the treatment. None reported headache during the treatment. Mild to moderate nausea and vomiting were observed during the days of combined therapy (2DG + RT) in 10 patients. No significant deterioration of the neurological status was observed during the treatment period. Seven patients were alive at 63, 43, 36, 28, 27, 19, and 18 months of follow-up. In these patients, the clinical and MR imaging studies did not reveal any late radiation effects.
CONCLUSIONS: Feasibility of administering the treatment (2DG + 5 Gy) is demonstrated by the excellent tolerance observed in all 20 patients. Further, the clinical and MR studies also show the absence of any brain parenchymal damage.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8641905     DOI: 10.1016/s0360-3016(96)85017-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  117 in total

1.  A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma.

Authors:  Murugesan K Gounder; Hongxia Lin; Mark Stein; Susan Goodin; Joseph R Bertino; Ah-Ng Tony Kong; Robert S DiPaola
Journal:  Biomed Chromatogr       Date:  2011-09-19       Impact factor: 1.902

Review 2.  Metabolic catastrophe as a means to cancer cell death.

Authors:  Shengkan Jin; Robert S DiPaola; Robin Mathew; Eileen White
Journal:  J Cell Sci       Date:  2007-02-01       Impact factor: 5.285

3.  Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models.

Authors:  Carl E Stafstrom; Jeffrey C Ockuly; Lauren Murphree; Matthew T Valley; Avtar Roopra; Thomas P Sutula
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

4.  Differential killing and radio-modifying effects of iodoacetate in mammalian normal and cancer cells.

Authors:  Usha Yadav; K B Anjaria; Rajesha Nairy; K B Shirsath; Utkarsha N Desai; Rajesh K Chaurasia; Nagesh N Bhat; B K Sapra
Journal:  Radiat Environ Biophys       Date:  2017-06-13       Impact factor: 1.925

5.  Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status.

Authors:  Songmi Noh; Ji-Ye Kim; Ja Seung Koo
Journal:  Tumour Biol       Date:  2014-05-22

6.  Regulation of glycolysis in head and neck squamous cell carcinoma.

Authors:  Dhruv Kumar
Journal:  Postdoc J       Date:  2017-01

Review 7.  From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors.

Authors:  Metin Kurtoglu; Theodore J Lampidis
Journal:  Mol Nutr Food Res       Date:  2009-01       Impact factor: 5.914

Review 8.  Linking the history of radiation biology to the hallmarks of cancer.

Authors:  Mary-Keara Boss; Robert Bristow; Mark W Dewhirst
Journal:  Radiat Res       Date:  2014-05-08       Impact factor: 2.841

Review 9.  Glucose deprivation-induced metabolic oxidative stress and cancer therapy.

Authors:  Andrean L Simons; David M Mattson; Ken Dornfeld; Douglas R Spitz
Journal:  J Cancer Res Ther       Date:  2009-09       Impact factor: 1.805

10.  Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress.

Authors:  Tanja Hadzic; Nükhet Aykin-Burns; Yueming Zhu; Mitchell C Coleman; Katie Leick; Geraldine M Jacobson; Douglas R Spitz
Journal:  Free Radic Biol Med       Date:  2010-01-18       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.